TY - JOUR
T1 - Long-term treatment of antipsychotics and combined therapy with other psychotropic medications inducing weight gain in patients with non-affective psychotic disorder
T2 - Evidence from GROUP, a longitudinal study
AU - Burin, Luisa M.
AU - Hahn, Margaret K.
AU - da Rocha, Neusa S.
AU - van Amelsvoort, Therese
AU - Bartels-Velthuis, Agna A.
AU - Bruggeman, Richard
AU - de Haan, Lieuwe
AU - Schirmbeck, Frederike
AU - Simons, Claudia J. P.
AU - van Os, Jim
AU - Cahn, Wiepke
N1 - Funding Information: The infrastructure for the GROUP study is funded through the Geestkracht programme of the Dutch Health Research Council (Zon-Mw, grant number 10-000-1001), and matching funds from participating pharmaceutical companies (Lundbeck, AstraZeneca, Eli Lilly, Janssen Cilag) and universities and mental health care organizations (Amsterdam: Academic Psychiatric Centre of the Academic Medical Center and the mental health institutions: GGZ Ingeest, Arkin, Dijk en Duin, GGZ Rivierduinen, Erasmus Medical Centre, GGZ Noord Holland Noord. Groningen: University Medical Center Groningen and the mental health institutions: Lentis, GGZ Friesland, GGZ Drenthe, Dimence, Mediant, GGNet Warnsveld, Yulius Dordrecht and Parnassia psycho-medical center The Hague. Maastricht: Maastricht University Medical Centre and the mental health institutions: GGzE, GGZ Breburg, GGZ Oost-Brabant, Vincent van Gogh voor Geestelijke Gezondheid, Mondriaan, Virenze riagg, Zuyderland GGZ, MET ggz, Universitair Centrum Sint-Jozef Kortenberg, CAPRI University of Antwerp, PC Ziekeren Sint-Truiden, PZ Sancta Maria Sint-Truiden, GGZ Overpelt, OPZ Rekem. Utrecht: University Medical Center Utrecht and the mental health institutions Altrecht, GGZ Centraal and Delta). Funding Information: NSR receives funding from Hospital de Clínicas de Porto Alegre Research Incentive Fund (FIPE), Fundação de Amparo à Pesquisa do RS (Research Support Foundation from RS)- 19/251-0001930-0, and Conselho Nacional de Desenvolvimento Científico e Tecnológico (National Council for Scientific and Technological Development)- 303652/2019-5. MKH holds the Michael and Kelly Meighen Chair in Psychosis Prevention (Centre for Addiction and Mental Health) (CAMH), and University of Toronto), and the Cardy Schizophrenia Research Chair (CAMH). Publisher Copyright: © 2022
PY - 2022/8/1
Y1 - 2022/8/1
N2 - Introduction: Antipsychotics (APs) can cause weight gain. Little is known about changes in weight when APs are combined with other psychotropics. This study examines the weight change in patients undergoing long-term treatment with APs or with AP combined with other psychotropics. Methods: Patients with non-affective psychotic disorder from the GROUP study were divided into three groups: AP medication group (APm) (n = 100), AP in combination with other psychotropics (APc) (n = 73), and medication-free (Meds-free) (n = 100). Weight change was examined at inclusion and after three years using a paired-sample t-test. An Independent-sample t-test was performed to evaluate weight change among patients taking clozapine, olanzapine, and quetiapine and individuals not taking these medications. Linear regression was performed to evaluate the association between covariates and weight. Results: Patients in the APm group [mean = 1.800 kg, t(99)=2.849, 95% CI(0.546, 3.054), p = 0.005] and the APc group [mean = 1.877 kg, t(72)=2.688, 95% CI(0.485, 3.268), p = 0.009] showed significant weight gain. Patients taking clozapine, olanzapine or quetiapine showed significant weight gain compared to those not taking these medications [mean difference=1.707 kg, t(271)= 2.061, 95% CI(0.077, 3.337), p = 0.040)]. Conclusion: Patients receiving APs and APs with other psychotropics gain weight during long-term treatment. It is possible that weight gain is mainly driven by APs.
AB - Introduction: Antipsychotics (APs) can cause weight gain. Little is known about changes in weight when APs are combined with other psychotropics. This study examines the weight change in patients undergoing long-term treatment with APs or with AP combined with other psychotropics. Methods: Patients with non-affective psychotic disorder from the GROUP study were divided into three groups: AP medication group (APm) (n = 100), AP in combination with other psychotropics (APc) (n = 73), and medication-free (Meds-free) (n = 100). Weight change was examined at inclusion and after three years using a paired-sample t-test. An Independent-sample t-test was performed to evaluate weight change among patients taking clozapine, olanzapine, and quetiapine and individuals not taking these medications. Linear regression was performed to evaluate the association between covariates and weight. Results: Patients in the APm group [mean = 1.800 kg, t(99)=2.849, 95% CI(0.546, 3.054), p = 0.005] and the APc group [mean = 1.877 kg, t(72)=2.688, 95% CI(0.485, 3.268), p = 0.009] showed significant weight gain. Patients taking clozapine, olanzapine or quetiapine showed significant weight gain compared to those not taking these medications [mean difference=1.707 kg, t(271)= 2.061, 95% CI(0.077, 3.337), p = 0.040)]. Conclusion: Patients receiving APs and APs with other psychotropics gain weight during long-term treatment. It is possible that weight gain is mainly driven by APs.
KW - Antipsychotic
KW - Combined therapy
KW - Non-affective psychotic disorders
KW - Psychotropic medication
KW - Weight gain
UR - http://www.scopus.com/inward/record.url?scp=85132701633&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.psychres.2022.114680
DO - https://doi.org/10.1016/j.psychres.2022.114680
M3 - Article
C2 - 35753222
SN - 0165-1781
VL - 314
JO - Psychiatry Research
JF - Psychiatry Research
M1 - 114680
ER -